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Abstract
Uveal melanoma (UM) is the most common primary intraocular malignancy in the Western world.
Recurrent mutations in GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, EIF1AX, and SF3B1 are described
as well as non-random chromosomal aberrations. Chromothripsis is a rare event in which chromo-
somes are shattered and rearranged and has been reported in a variety of cancers including UM.
SNP arrays of 249 UM from patients who underwent enucleation, biopsy or endoresection were
reviewed for the presence of chromothripsis. Chromothripsis was defined as ten or more break-
points per chromosome involved. Genetic analysis of GNAQ, GNA11, BAP1, SF3B1, and EIF1AX
was conducted using Sanger and next-generation sequencing. In addition, immunohistochemistry
for BAP1 was performed. Chromothripsis was detected in 7 out of 249 tumors and the affected
chromosomes were chromosomes 3, 5, 6, 8, 12, and 13. The mean total of fragments per chromo-
some was 39.8 (range 12-116). In 1 UM, chromothripsis was present in 2 different chromosomes.
GNAQ, GNA11 or CYSLTR2 mutations were present in 6 of these tumors and 5 tumors harbored a
BAP1 mutation and/or lacked BAP1 protein expression by immunohistochemistry. Four of these
tumors metastasized and for the fifth only short follow-up data are available. One of these meta-
static tumors harbored an SF3B1 mutation. No EIF1AX mutations were detected in any of the
tumors. To conclude, chromothripsis is a rare event in UM, occurring in 2.8% of samples and with-
out significant association with mutations in any of the common UM driver genes.
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1 | INTRODUCTION
Uveal melanoma (UM) is a relative rare disease and has a high mortality
rate due to metastasis in about half of all patients within 15 y after
diagnosis.1–3 It is the most common primary intra-ocular malignancy in
adults in the Western world.4 UM specific mutations in the alpha subu-
nit genes GNAQ and GNA11 are described as well as mutations in
BAP1, SF3B1, and EIF1AX.5–7 Mutations in the latter 3 genes are found
in 75% of all UM and are useful for prognostication of patients.8–10
BAP1-mutated UM gives rise to early-onset metastasis whereas
SF3B1-mutated UM gives rise to late-onset metastasis and EIF1AX-
mutated UM hardly metastasizes.8 Mutations in PLCB4 and CYSLTR2
are described in UM in a mutually exclusive manner to GNAQ or
GNA11 mutations but so far have not been associated with progno-
sis.11,12 Copy number alterations in chromosomes 1, 3, 6, and 8 are
correlated with prognosis of the UM patient.13,14 UM with EIF1AX,
SF3B1 and BAP1 mutations are associated with unique chromosomal
patterns, suggesting distinct UM subclasses. BAP1-mutated UM har-
bors entire chromosome copy number variations (CNVs) and entire
chromosome arm CNV anomalies (isochromosomes). UM with an
SF3B1 mutation is characterized by many structural variants, often
affecting the terminal ends of chromosomes and thus not entire
.......................................................................................................................................................................................
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
VC 2018 The Authors Genes, Chromosomes and Cancer Published by Wiley Periodicals, Inc.
Genes Chromosomes Cancer. 2018;1–7. wileyonlinelibrary.com/journal/gcc | 1
Received: 21 February 2018 | Revised: 26 April 2018 | Accepted: 28 April 2018
DOI: 10.1002/gcc.4
J_ID: Customer A_ID: GCC4 Cadmus Art: GCC4 Ed. Ref. No.: GCC-18-0046.R2 Date: 1-June-18 Stage: Page: 1
ID: jwweb3b2server Time: 18:28 I Path: D:/Wiley/Support/XML_Signal_Tmp_AA/JW-GCC#180024
452 wileyonlinelibrary.com/journal/gcc Genes Chrom som s C ncer. 2018;57:452–458.
chromosomes or chromosome arms.15 Besides these recurrent CNVs,
also other cytogenetic patterns are described such as polyploidy of the
genome, which occurs in 10%-15% of all UM.16 Another chromo-
somal anomaly described in UM is chromothripsis.14 This is a phenom-
enon in which many genomic rearrangements occurs in a single
chromosome or chromosome arm. It has been described in congenital
abnormalities, UM and a variety of other cancers such as bone cancer,
lung cancer, myelodysplastic syndrome (MDS), colorectal cancer, breast
cancer and neuroblastoma.14,17–21 Chromothripsis predicts a poor out-
come in skin melanoma and occur in high risk neuroblastoma, breast
cancer and MDS.18,20–22 A positive correlation between chromothripsis
and progression free survival was observed in metastatic colorectal
cancer.19 The clinical consequence of this phenomenon in UM remains
unclear.14 In this case series we report on chromothripsis in 7/249 UM.
The mechanism of chromothripsis remains elusive but several
hypotheses are described such as the formation of micronuclei, prema-
ture chromosome compaction (PCC), TP53 mutations and breakage-
fusion bridge cycles or irradiation.23–25 The formation of chromothrip-
sis involving telomere regions and 1 chromosome arm is described and
supports the hypothesis that events during the cell cycle are involved
in the formation of these chromosomal rearrangements.26 It is
hypothesized that chromothripsis occurs through the formation of
micronuclei that arise from lagging chromosomes or chromatid frag-
ments during mitosis.17,27–30 Moreover, these micronuclei are more
prone to DNA damage, with subsequently DNA nuclease repair by
non-homologous end joining (NHEJ), which could explain the chromo-
some reshuffling.17,27,30,31
2 | MATERIALS AND METHODS
2.1 | Inclusion
Patients with UM that underwent enucleation, endoresection or tumor
biopsy at the Erasmus University Medical Center (Rotterdam, The
Netherlands) or The Rotterdam Eye Hospital (Rotterdam, The Nether-
lands) between 1992 and 2017 were selected. SNP (single nucleotide
polymorphism) array data of the tumor were available from 249
patients. Chromothripsis was defined as 10 or more breakpoints per
chromosome detected with SNP array. A breakpoint is present
between 2 fragments with different copy number states in a chromo-
some. This study was approved by the local ethics committee and fol-
lowed the tenets of the Declaration of Helsinki. Informed consent was
obtained prior to treatment.
2.2 | SNP array
DNA was extracted from fresh tumor samples using the QIamp DNA-
mini kit (Qiagen, Hilden, Germany) following the manufacturer’s instruc-
tions. SNP array was performed using 200 ng of DNA as input for whole-
genome analysis (Illumina, San Diego, CA). The data were analyzed with
Nexus Copy Number 9.0 software (BioDiscovery Incorporated, El
Segundo, CA). The amount of copy number gains and losses was used to
determine the number of fragments. The total fragments were counted
including copy number neutral fragments as separate fragments.
2.3 | Mutation detection
Mutation analysis of GNAQ, GNA11, EIF1AX, SF3B1, and BAP1 was per-
formed with Sanger sequencing and Ion Torrent next-generation
sequencing (NGS; Thermo Fisher Scientific, Waltham, MA) as described
before.32 UM without a GNAQ or GNA11 mutation were sequenced
for PLCB4 and CYSLTR2. If the tumor did not harbor a mutation in
EIF1AX, SF3B1 or BAP1, mutation analysis for SRSF2 was performed.
SeqScape Software 3 (Applied Biosystems, Foster City, CA) and Inte-
grative Genomics Viewer (IGV) Version 2.3.68 (97; Broad Institute,
Cambridge, MA) was used to analyze the data. BAP1 immunohisto-
chemistry (IHC) was scored for the presence of nuclear BAP1 expres-
sion and performed as described previously.9
3 | RESULTS
3.1 | Patient characteristics
Chromothripsis was detected in the UM of 7 patients. These comprised
5 women and 2 men with a mean age at diagnosis of 57.4 y (range
46.2–73.4 y). Six patients underwent enucleation as primary treatment.
In 1 patient, primary treatment was followed by external beam radiother-
apy because of unclear surgical margins. One patient underwent brachy-
therapy as primary treatment, followed by enucleation almost 3 y later
due to tumor recurrence. Metastasis developed in 5 patients after 31.9–
78.7 mo. In 1 patient, a metastasis was located subcutaneously in
abdominal skin followed by a local relapse in the orbit. Three years later
metastases in the liver and bone were detected. One patient developed
metastasis in the bone, lung and paramediastinal nodes. Metastases in
the liver were present in 2 patients, together with cutaneous, muscular
and retroperitoneal nodal metastases in one of them. In 1 patient the
location of metastases is unknown. The mean disease free survival (DFS)
was 51.5 mo (range 15.5–99.0 mo). In Table T11 an overview of patient
characteristics is listed. For none of these patients was a family history
including UM or other related cancers documented.
3.2 | Tumor characteristics
Six tumors were located in the posterior choroid whereas 1 UM origi-
nated from the ciliary body. Mean largest tumor diameter was
13.5 mm (range 9.5–19 mm) and mean tumor thickness 7.5 mm (range
2–12 mm; Table 1). Three UM contained epithelioid cells and 4 were
classified as spindle cell type. Closed vascular loops were present in 2
of the 7 UM and extra-ocular extensions were found in 2 cases. Inflam-
matory infiltrate was insignificant in 2 tumors and present in 3 tumors,
of which extensively in one. Correlations of chromothripsis with patient
and tumor characteristics were not performed due to the limited num-
ber of cases.
BAP1 expression was present in 3 cases and absent in 4 cases.
Mutation analysis was performed in all 7 tumors (Figure F11). A mutation
in GNAQ,c.626A>C:p.(Gln209Pro), was detected in 2 tumors. A
GNA11 c.626A>T:p.(Gln209Leu) mutation was detected in the UM of
3 patients. The 2 UM without a GNAQ or GNA11 mutation did not har-
bor a mutation in PLCB4 but in 1 tumor a c.386T>A:p(Leu129Gln) in
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CYSLTR2 was detected (UM 6) . One c.1873C>T:p.(Arg625Cys) muta-
tion in SF3B1 was found (UM 1) but all tumors were wildtype for
EIF1AX. BAP1 mutations were detected in 4 patients: a c.89A>G:p.
(Glu31Gly; UM 2), a c.172_173del:p.(Ser58Profs*10) (UM 6), a
c.206_207insA:p.(Thr69Asnfs*5; UM 7) and a mutation 2 base pairs
after exon 5 (c.37512T>C; UM 4) resulting in alternative splicing
with a premature stop before the next predicted splice site (prediction
in Alamut Visual, Interactive Biosoftware, Rouen, France). Three of
these 4 BAP1-mutated UM had an absent BAP1 expression. In 1 tumor
a BAP1 mutation was not detected with NGS, although IHC revealed
lack of BAP1 expression. The 2 UM without a mutation in EIF1AX,
SF3B1 and BAP1 were wildtype for SRSF2 as well. Polyploidy occurred
in 2 out of 7 UM. See Figure 1 for an overview of mutation status and
BAP1 IHC.
3.3 | Chromothripsis
Eight chromosomes showed chromothripsis (Figure F22). One tumor har-
bored chromothripsis in 2 separate chromosomes (UM 5; Figure F33).
UM 7 (chromothripsis of chromosome 13) showed 8 fragments in chro-
mosome 16 as well. However, since this did not meet our criteria of
ten fragments, this chromosome was not included for further analysis.
Chromosome 3 and 6 were affected in 2 UM. Regarding chromosome
3, the breakpoints were not present in the BAP1 gene. Other affected
chromosomes were chromosome 5, 8, 12, and 13. The mean of the
total fragments per chromosome was 39.8 (range 12–116, Figure 1). In
4 of the 8 chromosomes, the B-allele frequencies indicates more than
2 copy number states of the separate chromosome fragments (Figures
2A and 3). In 5 cases (UM 2, UM 3, UM 4, UM 5, and UM 6) DNA from
blood was available for germline analysis using SNP array. No chromo-
thripsis was observed in these samples.
4 | DISCUSSION
Recurrent chromosomal aberrations have been described in detail in
UM, which are strongly correlated to the mutation status.15,33,34 In this
paper, another chromosomal aberration, called chromothripsis, is
described. Chromothripsis is characterized by ten to hundreds of chro-
mosome fragments that are shattered and randomly rearranged.17 This
is found in several malignancies with a mean pan-cancer prevalence of
1%-2%.14,31,35 Similar to other malignancies, chromothripsis is also rare
in UM. In one study, chromothripsis was observed in 2/25 UM.14 We
detected chromothripsis in 2.8% of the UM which is in line with the
low frequency rate as previously described.
A relation between prognosis and chromothripsis has been
reported in several studies on different malignancies. In high risk neuro-
blastoma, breast cancer and MDS, chromothripsis is correlated with a
poor outcome while in metastatic colorectal cancer a better progres-
sion free-survival has been described.15,17–19 Probably metastases with
chromothripsis respond better to therapy while the metastatic rate is
higher in cancers harboring chromothripsis. This might be true in UM
as well; however, no standardized treatment for metastatic UM is avail-
able yet. When such treatment is available it might be interesting to
compare the response to therapy in UM with and without
TABLE 1 Overview of clinical and tumor characteristics
Patient Sex Age DFS Metastasis Tumor diameter (mm) Tumor thickness (mm) Primary treatment
UM 1 F 46.3 42.7 Yes 14 10 Enucleation
UM 2 M 46.2 78.7 Yes 13 N.a. Enucleation
UM 3 F 57.4 47.4 Yes 9.5 2 Brachytherapy
UM 4 F 64.1 31.9 Yes 14 12 Enucleation
UM 5 M 55.8 99.0 No 12 4 Enucleation
UM 6 F 73.4 15.5 No 13 7.5 Enucleation
UM 7 F 58.6 45.4 Yes 19 9.5 Enucleation
Abbreviations: UM, uveal melanoma; F, female; M, male; Age, age at diagnosis in years; DFS, disease free survival in months; N.a., data not available.
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F IGURE 1 Overview of patient and tumor characteristics of uveal
melanoma with chromothripsis. The first row of blocks represents
the mutation status of GNAQ and GNA11. In UM 5 no mutation in
CYSLTR2 was detected and in UM 5 and UM 6 no mutations in
PLCB4 were found. In the second row of blocks the mutation
status of BAP1 and SF3B1 is given. None of the UM harbor an
EIF1AX mutation and UM 3 and UM 6 do not have a mutation in
SRSF2. The third row of blocks represents the BAP1 IHC staining.
Chromosome 3 status of the tumor, whether a patient developed
metastasis, the overall survival in years, the chromosome(s) with
chromothripsis and the number of fragments per chromosome with
chromothripsis are given below. UM, uveal melanoma; D, disomy;
M, monosomy; LOH, loss of heterozygosity; *, Polyploid tumor
[Color figure can be viewed at wileyonlinelibrary.com]
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chromothripsis. Metastatic disease was present in 5 out of 7 patients in
this report. Four of the metastasizing tumors harbored a BAP1 muta-
tion and or lacked BAP1 expression and in 1 tumor an SF3B1 mutation
was present. One of the 2 patients without metastatic disease did not
harbor a BAP1 or SF3B1 mutation in the tumor and the IHC showed a
positive BAP1 expression while from the other patient (harboring a
BAP1 mutation in the tumor) only short follow-up data were available
(16 mo). The overall poor prognosis of this cohort could be explained
by the mutations in BAP1 and SF3B1 since it is known that mutations
in these genes are correlated with a high risk of metastasis.8,10 There-
fore, there is no indication that chromothripsis itself causes metastatic
disease, but it is possible that the rate of SF3B1 and BAP1 mutations is
higher in UM with chromothripsis.
Other features of UM and the relation to chromothripsis could
have a clinical impact. In this cohort there were no UM with a hyper
mutable status, features of microsatellite instability or an indication of
germline mutations causing UM. Consequently, the relation between
chromothripsis and these tumor characteristics cannot be determined.
In about half of the UM, inflammation was present. The tumor with
extensive inflammation was the UM with a BAP1 mutation but without
metastatic disease. No conclusions about the immunogenicity can be
drawn because of the small numbers of UM with inflammation. Further
studies are needed to elucidate these relations and the outcome of
patients with chromothriptic UM. There are several risk factors known
for chromothripsis such as irradiation.23 In one case, brachytherapy
was followed by enucleation. Therefore, the chromothripsis in this UM
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F IGURE 2 Two examples of chromothripsis. (A) UM 1 showing chromothripsis of chromosome arm 6q with an additional gain of the
terminal short arm of chromosome 6. Note the 3 different copy number states in the chromothriptic chromosome. (B) UM 4 showing
chromothripsis of chromosome 3[Color figure can be viewed at wileyonlinelibrary.com]
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could be an irradiation effect. Other factors correlated with chromo-
thripsis formation are hyper- and polyploidization.36,37 For a long time
it was assumed that chromothriptic chromosomes only have 2 copy
number states.17,30,31 However, an observation was made in a subtype
of acute lymphoblastic leukemia, in which more copy number states
were found in chromothriptic chromosomes.38 In this study, 2 of the 7
UM (29%) were polyploid. Since polyploidy occurs in only 11% of all
large UM16 and chromothripsis is a rare event, this could explain the
co-occurrence of polyploid UM with chromothripsis. In addition, in our
cohort, 7 out of 8 chromothriptic chromosomes harbored more than 2
chromosomes. This observation was also made in the only other study
that described 2 cases of UM with chromothripsis.14 This suggests that
chromothripsis occurs in already duplicated chromosomes. Altered
chromosomes might even be more susceptible to chromosome lagging,
as 50% of the chromosomes with chromothripsis in this study have
more than 2 copy number states.38 Furthermore, chromothripsis can
occur in more than 1 chromosome in the same tumor.17 In our cohort,
more than 1 chromosome was affected in 1 tumor. It is noteworthy
that the affected chromosomes in this study included chromosomes 3,
6, and 8, since copy number variations in these chromosomes are cor-
related with mutation status in UM.15 This is in line with other studies
in which chromothripsis occur among known cancer driver genes.25,39
Nevertheless, chromothripsis-like patterns across different tumor types
showed a limited preference according to chromosome size. However,
chromosome 17 was most frequently affected and to a lesser degree
chromosomes 8, 11, and 12 in another study.26 This could be explained
by the fact that chromosome 17 also harbors TP53, an important can-
cer associated gene, which is correlated to chromothripsis as well.25
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F IGURE 3 A case with 2 chromothriptic chromosomes. UM 5 showing chromothripsis of (A) chromosome 6 and (B) chromosome 8. Note
the 3 copy number states and a general gain of the entire chromosomes[Color figure can be viewed at wileyonlinelibrary.com]
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To conclude, chromothripsis is a complex event that occurs in a
variety of cancers.14,18,20,25,26,40 This study shows chromothripsis in
almost 3% of UM affecting different chromosomes. Limitation of this
study was the small number of cases with chromothripsis. Although a
large patient cohort was investigated, the rare occurrence of chromo-
thripsis prohibited proper statistical analyses. Further studies are
needed to investigate the evolutionary advantage of this complex chro-
mosomal aberration.
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